Aktienanalyse wird geladen …
ROP · NASDAQ · Software - Application · USA
364,20 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 7,9 Mrd. | 1,54 Mrd. | 14,20 $ | 108,2 Mio. | 0,5 Mio · 0,4 % | 0,3 Mio · 0,2 % | 69,2 % | 19,4 % | 22,51 $ | 1,54 $ | 3,39 $ |
| 2024 | 7,04 Mrd. | 1,55 Mrd. | 14,35 $ | 108 Mio. | 0,4 Mio · 0,4 % | — | 69,3 % | 22 % | 21,13 $ | 1,35 $ | 3,08 $ |
| 2023 | 6,18 Mrd. | 1,38 Mrd. | 12,89 $ | 107,4 Mio. | 0,3 Mio · 0,3 % | — | 69,7 % | 22,4 % | 17,94 $ | 1,15 $ | 2,80 $ |
| 2022 | 5,37 Mrd. | 4,54 Mrd. | 42,55 $ | 106,8 Mio. | 0,3 Mio · 0,3 % | 0 Mio · 0 % | 69,9 % | 84,6 % | 6,22 $ | 1,11 $ | 2,54 $ |
| 2021 | 4,83 Mrd. | 1,15 Mrd. | 10,82 $ | 106,5 Mio. | 0,3 Mio · 0,3 % | — | 70,5 % | 23,8 % | 18,34 $ | 1,15 $ | 2,31 $ |
| 2020 | 4,02 Mrd. | 949,7 Mio. | 8,98 $ | 105,7 Mio. | 0,3 Mio · 0,3 % | — | 70,3 % | 23,6 % | 14,03 $ | 1,02 $ | 2,10 $ |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Bruttomarge | Nettomarge |
|---|---|---|---|---|---|---|
| Q2 2026 | 2,11 Mrd. | 1,17 Mrd. | 11,62 $ | 100,6 Mio. | 69,7 % | 55,4 % |
| Q1 2026 | 2,1 Mrd. | 508,9 Mio. | 4,87 $ | 104,6 Mio. | 69,4 % | 24,3 % |
| Q4 2025 | 2,06 Mrd. | 428,4 Mio. | 3,96 $ | 107,8 Mio. | 69,5 % | 20,8 % |
| Q3 2025 | 2,02 Mrd. | 398,5 Mio. | 3,68 $ | 108,4 Mio. | 69,5 % | 19,8 % |
| Q2 2025 | 1,94 Mrd. | 378,3 Mio. | 3,49 $ | 108,4 Mio. | 69,2 % | 19,5 % |
| Q1 2025 | 1,88 Mrd. | 331,1 Mio. | 3,06 $ | 108,2 Mio. | 68,7 % | 17,6 % |
| Q4 2024 | 1,88 Mrd. | 462,3 Mio. | 4,27 $ | — | 68,3 % | 24,6 % |
| Q3 2024 | 1,76 Mrd. | 367,9 Mio. | 3,40 $ | 108,1 Mio. | 69,2 % | 20,9 % |
Roche (SWX:ROP) Stock Looks Discounted As Its 60% Run Continues
Is Roche Holding (SWX:ROP) Undervalued Following Its Phase 3 IgA Nephropathy Win?
Roche Holding (SWX:ROP) Phase III Trial Met Its Primary Endpoint In Follicular Lymphoma
Illumia Appoints Don Smith to Lead Higher Education Portfolio
DAT: Spot van rate falls 20 cents in steepest August pullback on record
Roper Technologies' Procare Acquires Child Care Management Platform Playground
Roper Technologies Inc. is a diversified technology company focused on niche markets through a portfolio of vertically oriented software, network software, and technology-enabled products. Roper Technologies Inc. develops mission-critical solutions used by customers in healthcare, education, legal services, construction, insurance, transportation, laboratory operations, and other specialized industries. Its products and services include application management software, data and workflow tools, cloud-based platforms, and engineered devices that support operational efficiency, compliance, payments, and information management. The company operates through three main segments: Application Software, Network Software, and Technology Enabled Products, with businesses that often serve recurring, workflow-based customer needs. Based in Sarasota, Florida, Roper Technologies Inc. plays a significant role in delivering specialized software and connected solutions for markets where reliability, integration, and industry-specific functionality are essential.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest ROP und jede andere Aktie unbegrenzt.